Clozapine: A comparison with other novel antipsychotics

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 12, 1999, Pages 30-34

  Fleischhacker, W Wolfgang ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; ZOTEPINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; DIBENZOTHIEPINS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; HUMANS; PIRENZEPINE; PLACEBOS; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0032978562     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Angst J, Bente D, Berner P, et al. Das klinische Wirkungsbild von Clozapin. Pharmakopsychiatrie 1971;4:201-211
2. Angst J, Jaenicke U, Padrutt A, et al. Ergebnisse eines Doppelblindversuchs von HF1854 im Vergleich zu Levomepromazin. Pharmakopsychiatrie 1971;4:192-200
3. Berzewski H, Helmchen H, Hippius H, et al. Das klinische Wirkungsspektrum eines neuen Dibenzodiazepin-Derivats. Arzneimittelforschung 1969;19:495-496
4. Breier A, Schreiber JL, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
5. 2 dopamine antagonists. Neuropsychopharmacology 1996;14 (3 suppl):35S-39S
6. Gross H, Langner E. Das Wirkungsprofil eines chemisch neuartigen Breitbandneuroleptikums der Dibenzodiazepingruppe. Wien Med Wochenschr 1969;116:814-816
7. Lindstrom LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988;77:524-529
8. McGurk SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999;60(suppl 12):24-29
9. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-897
10. Morris S, Hogan T, McGuire A. The cost-effectiveness of clozapine: a survey of the literature. Clin Drug Invest 1998;15:136-152
11. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-677
12. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989;99(suppl):S47-S53
13. Kurz M, Hummer M, Oberbauer H, et al. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology (Berl) 1995;118:52-56
14. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
15. Hummer M, Kurz M, Barnas C, et al. Clozapine-induced transient white blood count disorders. J Clin Psychiatry 1994;55:429-432
16. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
17. Fleischhacker WW, Hummer M. Drug treatment of schizophrenia in the 1990s: achievements and future possibilities in optimising outcomes. Drugs 1997;53:915-929
18. Bondolfi G, Dufour H, Patris M, et al, and the Risperidone Study Group. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998;155:499-504
19. Beuzen JN, Birkett M, Kiesler G, et al. Olanzapine vs clozapine in resistant schizophrenic patients: results of an international double-blind randomised clinical trial. Proceedings of the 21st Congress of the Collegium Internationale Neuropsychopharmacologicum: July 14, 1998; Glasgow, Scotland. Abstract PT07051
20. Meyer-Lindenberg A, Gruppe H, Bauer U, et al. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997;30:35-42
21. Heinrich K, Klieser E, Lehmann E, et al. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:129-137
22. Klieser E, Strauss WH, Lemmer W. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. Acta Psychiatr Scand 1994;89(suppl 380):68-73
23. Flynn SW, MacEwan GW, Altman S, et al. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 1998;31:25-29
24. Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59:69-75
25. Fogelson DL, Sternbach H, Payne D. A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1997;17:492-494
26. Daniel DG, Goldberg TE, Weinberger DR, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996;153:417-419
27. Still DJ, Dorson PG, Crismon ML, et al. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996:47:1382-1384
28. Fleischhacker WW, Hummer M, Kurz M, et al. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994:55(9, suppl B):78-81
29. Miller DD. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Ann Clin Psychiatry 1996; 8:99-109
30. Pollack S, Lieberman JA, Fleischhacker WW, et al. A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effects. Psychopharmacol Bull 1995;31:315-320
31. VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996;153:1579-1584
32. Philpott NJ, Marsh JC, Gordon-Smith EC, et al. Aplastic anaemia and remoxipride [letter]. Lancet 1993;342:1244-1245
33. Lacey RL, Preskorn SH, Jerkovich GS. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics? [letter] Am J Psychiatry 1995;152:1401
34. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-920